← Patent-cliff monitor small molecule DOPTELET AVATROMBOPAG MALEATE
Loss of exclusivity July 2032 FDA regulatory exclusivity expiry
Company AkaRx → See this company's full patent-cliff portfolio Drug detail Brand name DOPTELET Active ingredient AVATROMBOPAG MALEATE Strength EQ 20MG BASE Dosage form TABLET Route ORAL Modality Small molecule FDA approval May 2018 Marketing status RX
Listed patents Patent Expires Type 7638536 July 2027 substance, product
Regulatory exclusivity Code Expires ODE-548 July 2032 I-974 July 2028 ODE-246 June 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.